ZFHX3
ZFHX3 (Zinc finger homeobox protein 3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Endometrial cancer, Breast cancer and 5 more.
Overview
Transcriptional regulator which can act as an activator or a repressor. Inhibits the enhancer element of the AFP gene by binding to its AT-rich core sequence. In concert with SMAD-dependent TGF-beta signalling can repress the transcription of AFP via its interaction with SMAD2/3.
Open Targets scores its association with cancer at 0.81 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.67, somatic mutation 0.92). IntOGen calls it a driver in 17 cohorts (4 activating, 13 loss-of-function), covering Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Hepatocellular Carcinoma, Osteosarcoma, Plasma Cell Myeloma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ZFHX3 (Zinc finger homeobox protein 3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Endometrial cancer, Breast cancer and 5 more.
- 1 · What it is
ZFHX3 (Zinc finger homeobox protein 3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Endometrial cancer, Breast cancer and 5 more.
- 2 · What goes wrong in cancer
Transcriptional regulator which can act as an activator or a repressor. Inhibits the enhancer element of the AFP gene by binding to its AT-rich core sequence.
- 3 · How drugs use it
No product in this corpus aims at ZFHX3 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:777 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q15911 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000140836 (association with cancer (MONDO_0004992) 0.81; per-cancer scores at or above 0.5: colorectal cancer 0.53, gastric cancer 0.51, prostate cancer 0.67, endometrial cancer 0.59, melanoma 0.52, thyroid cancer 0.50 (GraphQL API, CC0)); IntOGen ZFHX3 (driver in 17 cohorts (Act 4, LoF 13); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional regulator which can act as an activator or a repressor. Inhibits the enhancer element of the AFP gene by binding to its AT-rich core sequence. In concert with SMAD-dependent TGF-beta signalling can repress the transcription of AFP via its interaction with SMAD2/3. Regulates the circadian locomotor rhythms via transcriptional activation of neuropeptidergic genes which are essential for intercellular synchrony and rhythm amplitude in the suprachiasmatic nucleus (SCN) of the brain. Regulator of myoblasts differentiation through the binding to the AT-rich sequence of MYF6 promoter and promoter repression. Down-regulates the MUC5AC promoter in gastric cancer. Location: Nucleus; Cytoplasm (UniProt). Locus 16q22.2-q22.3 (HGNC).
- Prostate cancer: Open Targets association 0.67 with prostate cancer (MONDO_0008315); IntOGen driver in 3 cohorts (PRAD)
- Endometrial cancer: Open Targets association 0.59 with endometrial cancer (MONDO_0011962); IntOGen driver in 3 cohorts (UCEC)
- Breast cancer: Open Targets association 0.61 with breast cancer (MONDO_0007254); IntOGen driver in 2 cohorts (BRCA)
- Thyroid cancer: Open Targets association 0.50 with thyroid cancer (MONDO_0002108); IntOGen driver in 2 cohorts (WDTC)
- Hepatocellular carcinoma: IntOGen driver in 2 cohorts (HCC)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 4 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 13 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ZFHX3" OR ABSTRACT:"ZFHX3" OR TITLE:"zinc finger homeobox 3" OR ABSTRACT:"zinc finger homeobox 3" OR TITLE:"Zinc finger homeobox protein 3" OR ABSTRACT:"Zinc finger homeobox protein 3" OR TITLE:"ZNF927" OR ABSTRACT:"ZNF927" OR TITLE:"FLJ26184" OR ABSTRACT:"FLJ26184" OR TITLE:"ATBF1" OR ABSTRACT:"ATBF1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZFHX3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCDKN1B
Shares Thyroid cancer, Hepatocellular carcinoma, Breast cancer (all types), IntOGen.
- TargetPABPC1
Shares Thyroid cancer, Bladder & urothelial cancer, Hepatocellular carcinoma, IntOGen.
- TargetSTAG2
Shares Thyroid cancer, Endometrial cancer, Bladder & urothelial cancer, Breast cancer (all types).
- TargetEPHA3
Shares Thyroid cancer, Breast cancer (all types), IntOGen, Prostate cancer.
- TargetEPHA7
Shares Thyroid cancer, Hepatocellular carcinoma, IntOGen, Open Targets Platform.
- TargetEIF1AX
Shares Thyroid cancer, Endometrial cancer, IntOGen, Prostate cancer.
- TargetHRAS
Shares Thyroid cancer, Bladder & urothelial cancer, Breast cancer (all types), IntOGen.
- TargetPPARG
Shares Thyroid cancer, Endometrial cancer, Open Targets Platform.